In preclinical studies, selective PPARα (fenofibrate), PPARγ (pioglitazone) and PPARδ (GW501516) were compared to the pan-PPAR agonist, lanifibranor, and indicated that pan-PPAR agonism lowers experimental NASH by combining the beneficial effects of the three PPAR isotypes (373). The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.